Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsRodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Isavuconazole: A New Option for the Management of Invasive Fungal Infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelAntifungal pharmacokinetics and pharmacodynamicsSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisPharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment.Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Global Aspects of Triazole Resistance in Aspergillus fumigatus with Focus on Latin American Countries.Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q26740837-5FBEFB6E-4A5F-4A4C-98CC-6EFEC3CA5984Q26744049-520DCE0C-34F2-43A1-8567-31B8FE86AA9DQ28067726-E492C5C9-D4C8-4AEE-B127-8D9868737F7CQ33689767-FBFC3A17-3A4C-4233-B651-D8ABD5AE2D3BQ34474946-466F2262-3A2C-42D6-A2DA-E34198A623F5Q35076974-EF912481-0E99-4D2D-BF93-FDC6A803FADBQ35385554-5A20BEDD-D8B2-453B-9F3D-9C9CCB4DA791Q35663841-2851D4FE-4924-40DC-B01B-D47276EC0408Q36396166-C7752FBB-4F57-47C1-9E29-B537888F3D88Q36439102-03AB72FE-FDF3-4107-8CCF-8AE0D88CC561Q36887855-D48F9B03-7B40-418E-9A5F-D801E1D35A59Q36977398-A47F3EDC-40BB-4E12-A3E4-90BC64C7BF38Q37096795-257287AA-2D18-4980-AF27-18B0FED7CB16Q37119937-512DF2B8-7BE3-4DC6-B749-25AD08906790Q37203893-BFD21137-4924-43FC-B76C-DC3D9A85FA4AQ38285488-B32E335E-EBEB-4DAE-9E22-DB1F01DE9322Q38436002-038BDEDF-80FA-41A4-9A2B-D5D86EEE743BQ38644817-781292E3-6A9F-41C7-BBC5-B120388BEB70Q38829932-E950DD87-0517-4D72-8C56-7071C2CE5A47Q38919690-8E18AFF0-ECE2-4568-964F-A986ECF18DFAQ38939506-9B32C202-BC02-4265-9CDB-A15D27CD509AQ38987096-928244ED-7A38-4167-BA59-40451F35C488Q39003715-D204EA61-C2A5-4B39-A995-67F0057DBF08Q40040786-045D7D85-15CC-4D54-9A5E-BF35B5363EE1Q40083822-FC690784-E7A6-4F37-B80E-6F915E163271Q40140001-04A91F9F-A24C-4169-BEB5-AF78981E2EBFQ41188300-40F79DF2-3EC6-4886-9A9B-39285086D3D2Q47098888-9E03E240-3AF2-4C9D-9B56-EB2F71C78A15Q47151374-040EBFA4-5C13-42E1-BF91-08E9002B9010Q49167496-84E3D7A5-C171-4261-A69E-0EC377583398Q50094753-7C224C68-9F90-45FD-9FC5-6F5E2AE419AAQ54214603-F41115AA-3810-44A0-B3A8-8CF94609A3B9
P2860
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Isavuconazole (BAL4815) pharma ...... ates of Aspergillus fumigatus.
@en
Isavuconazole
@nl
type
label
Isavuconazole (BAL4815) pharma ...... ates of Aspergillus fumigatus.
@en
Isavuconazole
@nl
prefLabel
Isavuconazole (BAL4815) pharma ...... ates of Aspergillus fumigatus.
@en
Isavuconazole
@nl
P2093
P2860
P921
P356
P1476
Isavuconazole (BAL4815) pharma ...... lates of Aspergillus fumigatus
@en
P2093
Alexander J Lepak
Jamie Vanhecker
Karen Marchillo
P2860
P304
P356
10.1128/AAC.01355-13
P407
P50
P577
2013-10-07T00:00:00Z